Kelley D J, Pavelic Z P, Gapany M, Stambrook P, Pavelic L, Gapany S, Gluckman J L
Department of Otolaryngology-Head and Neck Surgery, College of Medicine, University of Cincinnati, Ohio 45267-0528.
Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):411-4. doi: 10.1001/archotol.1993.01880160057009.
One established mechanism of multidrug resistance is elevated expression of P-glycoprotein. The expression of P-glycoprotein by immunohistochemistry was examined in squamous cell carcinomas of the head and neck using a newly developed monoclonal antibody, UIC2, which is specific to the human MDR1 gene product and recognizes an external epitope of the protein. P-glycoprotein was detected in 60% of the samples. MDR1 expression was compared with clinical response to chemotherapy in eight patients who received MDR1-dependent drugs and response was accurately predicted in seven (89%) of eight patients. Positive P-glycoprotein staining correlated with the degree of tumor differentiation, but not with other clinical factors. Therefore, analyzing the expression of P-glycoprotein may play a role when planning chemotherapeutic regimens for patients with head and neck cancer and may be an additional prognostic and diagnostic tool in these patients.
一种已确立的多药耐药机制是P-糖蛋白表达升高。使用一种新开发的单克隆抗体UIC2对头颈部鳞状细胞癌进行免疫组织化学检测P-糖蛋白的表达，该抗体对人类MDR1基因产物具有特异性，并识别该蛋白的一个外部表位。在60%的样本中检测到了P-糖蛋白。对8例接受依赖MDR1药物治疗的患者，将MDR1表达与化疗临床反应进行比较，8例患者中有7例（89%）的反应得到了准确预测。P-糖蛋白染色阳性与肿瘤分化程度相关，但与其他临床因素无关。因此，分析P-糖蛋白的表达在为头颈部癌患者制定化疗方案时可能发挥作用，并且可能是这些患者的一种额外的预后和诊断工具。
